JP2003335776A5 - - Google Patents

Download PDF

Info

Publication number
JP2003335776A5
JP2003335776A5 JP2002229532A JP2002229532A JP2003335776A5 JP 2003335776 A5 JP2003335776 A5 JP 2003335776A5 JP 2002229532 A JP2002229532 A JP 2002229532A JP 2002229532 A JP2002229532 A JP 2002229532A JP 2003335776 A5 JP2003335776 A5 JP 2003335776A5
Authority
JP
Japan
Prior art keywords
phenyl
benzoazosin
butoxyethoxy
sulfinyl
imidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002229532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003335776A (ja
JP4316203B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2003335776A publication Critical patent/JP2003335776A/ja
Publication of JP2003335776A5 publication Critical patent/JP2003335776A5/ja
Application granted granted Critical
Publication of JP4316203B2 publication Critical patent/JP4316203B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002229532A 2001-08-08 2002-08-07 二環性化合物、その製造法および用途 Expired - Lifetime JP4316203B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-240750 2001-08-08
JP2001240750 2001-08-08
JP2002-66809 2002-03-12
JP2002066809 2002-03-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006355701A Division JP4358851B2 (ja) 2001-08-08 2006-12-28 二環性化合物、その製造法および用途

Publications (3)

Publication Number Publication Date
JP2003335776A JP2003335776A (ja) 2003-11-28
JP2003335776A5 true JP2003335776A5 (enExample) 2007-12-13
JP4316203B2 JP4316203B2 (ja) 2009-08-19

Family

ID=26620186

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2002229532A Expired - Lifetime JP4316203B2 (ja) 2001-08-08 2002-08-07 二環性化合物、その製造法および用途
JP2006355701A Expired - Lifetime JP4358851B2 (ja) 2001-08-08 2006-12-28 二環性化合物、その製造法および用途
JP2009147839A Expired - Lifetime JP5275148B2 (ja) 2001-08-08 2009-06-22 二環性化合物、その製造法および用途
JP2013050937A Pending JP2013136629A (ja) 2001-08-08 2013-03-13 二環性化合物、その製造法および用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006355701A Expired - Lifetime JP4358851B2 (ja) 2001-08-08 2006-12-28 二環性化合物、その製造法および用途
JP2009147839A Expired - Lifetime JP5275148B2 (ja) 2001-08-08 2009-06-22 二環性化合物、その製造法および用途
JP2013050937A Pending JP2013136629A (ja) 2001-08-08 2013-03-13 二環性化合物、その製造法および用途

Country Status (13)

Country Link
US (7) US7371772B2 (enExample)
EP (3) EP1889839B1 (enExample)
JP (4) JP4316203B2 (enExample)
AR (1) AR034985A1 (enExample)
AT (2) ATE539062T1 (enExample)
AU (1) AU2002328092A1 (enExample)
CA (2) CA2459172C (enExample)
DE (1) DE60235632D1 (enExample)
DK (2) DK1423376T3 (enExample)
ES (2) ES2339340T3 (enExample)
PE (1) PE20030329A1 (enExample)
PT (2) PT1423376E (enExample)
WO (1) WO2003014105A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1889839B1 (en) 2001-08-08 2013-11-06 Tobira Therapeutics, Inc. Bicyclic compound, production and use as HIV inhibitors
CN1649847A (zh) * 2002-03-12 2005-08-03 武田药品工业株式会社 制备旋光亚砜衍生物的方法
US7288654B2 (en) 2003-02-07 2007-10-30 Takeda Pharmaceutical Company Ltd Fused-ring pyridine derivative, process for producing the same, and use
WO2004069834A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 三環性化合物、その製造方法および用途
US20060160864A1 (en) * 2003-02-07 2006-07-20 Mitsuru Shiraishi Acrylamide derivative, process for producing the same, and use
CA2562388A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion-stabilized preparation
WO2005089716A1 (ja) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited 高含量化製剤
US20050260139A1 (en) * 2004-03-30 2005-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on anticholinergics and CCR2 receptor antagonists
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
JPWO2006059716A1 (ja) * 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
BRPI0914457A2 (pt) * 2008-10-17 2015-10-27 Invasc Therapeutics Inc composto, composição farmacêutica, método para reduzir angiotensão convertendo atividade de enzima, método para tratar uma perturbação relacionada com o sistema de renina-angiotensina aldosterona, método para tratar derrame cerebral
SG10201407881WA (en) 2009-11-27 2015-01-29 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
WO2012047630A2 (en) * 2010-09-27 2012-04-12 Martin Teintze N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP3922246A1 (en) * 2014-03-21 2021-12-15 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
EP3148538A4 (en) * 2014-06-02 2018-01-17 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
JP2017526713A (ja) 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
CN107207538A (zh) 2014-12-23 2017-09-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法
KR20170113596A (ko) 2015-02-10 2017-10-12 토비라 쎄라퓨틱스, 인크. 섬유증의 치료를 위한 세니크리비록
KR101938036B1 (ko) * 2015-04-16 2019-01-14 서울대학교산학협력단 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법
RU2019101242A (ru) * 2016-06-21 2020-07-21 Тобира Терапьютикс, Инк. Очищенный ценикривирок и очищенные промежуточные соединения для получения ценикривирока
BR112019003987A2 (pt) * 2016-08-31 2019-05-28 Tobira Therapeutics Inc formas sólidas de mesilato de cenicriviroc e processos de produção das formas sólidas de mesilato de cenicriviroc
EP3567028B1 (en) * 2016-12-09 2022-01-05 Medshine Discovery Inc. Biphenyl compound as ccr2/ccr5 receptor antagonist
MX2019009909A (es) 2017-02-24 2019-10-14 Genfit Composiciones farmaceuticas para terapia de combinacion.
KR20200116912A (ko) * 2018-02-02 2020-10-13 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 카르복실산기를 포함하는 질소-함유 벤조헤테로시클 화합물, 이의 제조 방법 및 이의 용도
EP3749697A4 (en) 2018-02-05 2021-11-03 Bio-Rad Laboratories, Inc. CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
WO2020207263A1 (zh) * 2019-04-08 2020-10-15 四川科伦博泰生物医药股份有限公司 苯并咪唑化合物、其制备方法及其用途
US20230002360A1 (en) * 2019-06-24 2023-01-05 Shenzhen Lingfang Biotech Co.,Ltd Heterocycloalkyl compounds as CCR2 / CCR5 antagonists
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
EP4159730A4 (en) * 2020-05-22 2024-05-01 Medshine Discovery Inc. PYRIDINE DERIVATIVE AND APPLICATION THEREOF
CN112472678A (zh) * 2020-11-12 2021-03-12 澳美制药厂有限公司 肾素那敏制剂及其制备方法
WO2023143112A1 (zh) * 2022-01-26 2023-08-03 无锡瓴方生物医药科技有限公司 氮杂苯并八元环化合物的盐型、晶型及其应用
CN118987211B (zh) * 2023-05-22 2025-09-19 无锡瓴方生物医药科技有限公司 一种联合用药物组合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
ATE199721T1 (de) 1994-07-04 2001-03-15 Takeda Chemical Industries Ltd Phosphonsäure verbindungen imre herstellung und verwendung
RU2167649C2 (ru) 1995-08-11 2001-05-27 Ниссан Кемикал Индастриз, Лтд. Способ получения твердой дисперсии умеренно водорастворимого лекарственного вещества (варианты) и фармацевтическая композиция
JP3995414B2 (ja) 1997-10-20 2007-10-24 大日本住友製薬株式会社 安定な医薬組成物
US6172061B1 (en) * 1997-12-19 2001-01-09 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative
AU5301599A (en) * 1998-08-20 2000-03-14 Takeda Chemical Industries Ltd. Quaternary ammonium salts and their use
CA2244097A1 (en) 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
AU1690100A (en) 1998-12-21 2000-07-12 Takeda Chemical Industries Ltd. Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5
DE60013583T8 (de) 1999-04-12 2006-06-08 Shionogi & Co., Ltd. Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs
JP2001026586A (ja) 1999-05-07 2001-01-30 Takeda Chem Ind Ltd 環状化合物およびその用途
AU6870600A (en) 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
EP1889839B1 (en) * 2001-08-08 2013-11-06 Tobira Therapeutics, Inc. Bicyclic compound, production and use as HIV inhibitors
CN1649847A (zh) 2002-03-12 2005-08-03 武田药品工业株式会社 制备旋光亚砜衍生物的方法
CA2562388A1 (en) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion-stabilized preparation
WO2005089716A1 (ja) * 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited 高含量化製剤
JPWO2006059716A1 (ja) 2004-12-03 2008-06-05 武田薬品工業株式会社 固形製剤
WO2008030853A2 (en) 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
MX2012011415A (es) 2010-04-02 2013-02-26 Phivco 1 Llc Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico.
JP6155193B2 (ja) 2010-11-18 2017-06-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ ヒト免疫不全ウイルスに対する抗体動員及び進入阻害活性を有する二官能性分子
JP6178788B2 (ja) 2011-06-27 2017-08-09 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） Ｃｃｒ２アンタゴニストペプチド
UA115807C2 (uk) 2013-05-15 2017-12-26 Тобіра Терап'Ютикс, Інк. Композиція (варіанти) ценікривіроку і спосіб її одержання та застосування (варіанти)
EP3922246A1 (en) 2014-03-21 2021-12-15 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of fibrosis
CN107207538A (zh) 2014-12-23 2017-09-26 妥必徕疗治公司 制备cenicriviroc及相关类似物的方法
KR20170113596A (ko) 2015-02-10 2017-10-12 토비라 쎄라퓨틱스, 인크. 섬유증의 치료를 위한 세니크리비록

Similar Documents

Publication Publication Date Title
JP2003286379A5 (enExample)
IS8340A (is) Fjölbreyttar myndir 3-(4-amínó-1-oxó-1,3 díhýdró-ísóindol-2-ýl)-piperidín-2,6-díons
IS8265A (is) Súksín og malónat salt af trans-4-(IR,3S)-6-klór-3-fenýlindan-1-ýl)-1,2,2-trímetýlpíperasín og notkun sem lyf
DE60314124D1 (de) 2-(2,6-dichlorphenyl)-diarylimidazole
JP2005510235A5 (enExample)
JP2003526716A5 (enExample)
JP2004093553A5 (enExample)
PT1663236E (pt) Combinação compreendendo n-(3-metoxi-5-metilpirazin-2-il)-2-(4- [1,3,4-oxadiazol-2-il]fenil)piridina-3-sulfonamida e um bifosfonato
JP2009520682A5 (enExample)
JP2007119504A5 (enExample)
JP2003215047A5 (enExample)
JP2003160581A5 (enExample)
AU2003234796A1 (en) Diimonium salt mixtures, aminium salts mixtures and use thereof
IS8461A (is) 2-(3,4-dímetýlfenýl)-4-{[2-hýdroxý-3'(1H-tetrasól-5-ýl)bífenýl-3-ýl]-hýdrasónó}-5-metýl-2,4-díhýdrópýrasól-3-ónkólín
JP2005536763A5 (enExample)
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
JP2005005118A5 (enExample)
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
DE60117131D1 (de) Pyridazinyl phenyl hydrazone nützlich gegen kongestives herzversagen
JP2002277470A5 (enExample)
ITTO20020157A0 (it) Macchina depallettizzatrice.
IS8007A (is) 4-(2-fenýlsúlfanýl-fenýl)-1,2,3,6-tetrahýdrópýridín afleiður sem serótónín endurupptöku hindrar
JP2004252992A5 (enExample)
JP2002275230A5 (enExample)
JP2008001637A5 (enExample)